Policy moves fast. You shouldn’t have to chase it.
Built by a former cannabis regulator, Policy, Decoded is your high-signal daily briefing for operators, investors, and policymakers navigating the collision of law, regulation, and business.
Federal cannabis reform feels as stalled as ever. The DEA has gone quiet on rescheduling. McConnell is taking aim at hemp-derived THC in the Farm Bill. Meanwhile, states are hiking cannabis taxes, Colorado labs are inflating potency results, and New York’s crackdown on illegal smoke shops isn’t slowing the illicit trade. Add in big polling numbers for legalization and early signs of psychedelic reform in Alaska, and you’ve got a policy landscape in flux.
☕ Read it with your morning coffee.
📈 Reference it in your strategy meeting.
📬 Forward it to your compliance lead.
Start smarter. Move faster. Stay ahead.
Start here — the day’s most important development, decoded for impact.
📌 What Happened: Six months after the U.S. Department of Health and Human Services recommended moving cannabis to Schedule III, the DEA has offered no update on the rescheduling process (Cannabis Business Times). The agency’s silence is fueling frustration across the industry as operators, investors, and regulators wait for clarity on one of the most consequential federal decisions in decades.
💡 Why It Matters: Rescheduling is more than symbolic. Moving cannabis to Schedule III would eliminate 280E tax penalties, open research pathways, and send a powerful signal that federal attitudes are finally shifting. The longer the DEA stalls, the harder it becomes for businesses to plan for taxes, compliance, and capital allocation under the rules that may or may not exist next year.
This delay also underscores how fragile federal cannabis momentum remains. Even with overwhelming public support and an HHS recommendation on the table, progress is still subject to the grinding pace of bureaucratic and political calculus in Washington.
🧠 THC Group Take: Do not mistake silence for indecision. The DEA is not debating whether to reschedule; it is calculating when the timing makes the most sense politically. That is how federal agencies operate on issues carrying this kind of baggage.
You cannot build a business on regulatory “what ifs.” Federal relief may arrive in time, but until it does, treat 280E as the rule and structure growth accordingly. Betting the farm on Schedule III could leave you dangerously exposed if Washington continues to crawl.
Fast-moving headlines, flagged for what matters.
Sen. Mitch McConnell, who once engineered federal hemp legalization, is now leading a push to ban intoxicating hemp-derived products in the next Farm Bill, with a committee vote expected this week (Marijuana Moment). His target: the loophole that unleashed delta-8, THC beverages, and a wave of psychoactive hemp products across the country. Thankfully for hemp operators, McConnell’s grip on his caucus isn’t what it once was, but the pressure to rein in hemp’s gray market is building fast. This isn’t the time to assume gridlock will save the day, though. The politics of intoxicating hemp are shifting, and not in the industry’s favor.
Natural Medicine Alaska has submitted the first signatures to qualify a 2026 ballot measure that would legalize psilocybin, mescaline, DMT, and psilocin under a “grow, gather, gift” model (Marijuana Moment). If approved, the initiative would allow personal use and home cultivation alongside licensed healing centers, making it one of the broadest state-level psychedelics proposals to date.
California, Maine, and Minnesota are hiking cannabis taxes in 2025, leaning on the industry to help balance budgets as revenue from local and federal sources dries up (MJBizDaily). It’s the latest example of states treating cannabis as a fiscal pressure valve, even as operators struggle with price compression and illicit competition. The pattern is clear. Policymakers want the benefits of legalization without confronting the math problem their own tax structures created. High taxes don’t just strain businesses; they hand the illicit market an enduring advantage.
Despite a crackdown, thousands of unlicensed cannabis shops remain active across New York City, undermining the legal market and siphoning tax revenue (Crain’s NY). State regulators and city officials are struggling to enforce closures as limited resources and legal challenges let illicit operators stay steps ahead. Enforcement efforts face a delicate balancing act: crack down too hard and you risk recreating the harms of prohibition; move too softly and the legal market never gains traction. Migrating consumers from illicit to licensed stores is a noble goal, but building a competitive landscape that makes it possible is proving far more daunting.
An audit of Colorado cannabis testing labs found widespread inflation of THC potency in marijuana flower, with some results exaggerating levels by as much as 30% (MJBizDaily). State regulators are weighing stricter oversight and penalties for labs caught manipulating results. This highlights the challenge of maintaining consumer trust in potency labels and exposes regulatory gaps that still let bad actors game the system.
The deeper pattern behind today’s moves — and why it matters next.
🧾 Context: Nearly 9 in 10 Americans now support legalizing marijuana in some form, according to new Pew polling. Support runs deep across party lines, with broad majorities of Democrats, Republicans, and independents onboard (Marijuana Moment). Only 11% say cannabis should remain fully illegal, a staggering reversal for an issue once treated as political kryptonite.
🔎 What It Signals: Federal marijuana prohibition has no public mandate left. Congress isn’t frozen because voters are ambivalent. It’s frozen because lawmakers lack urgency, and the political machinery grinds slower than cultural change. Senate leadership has treated cannabis as a side show for years, content to let states experiment and absorb the fallout. Meanwhile, the gap between federal policy and on-the-ground reality grows wider every day.
🧠 THC Group Take: If you’re still waiting for Congress to bless this industry, you’re in the wrong game. Lawmakers have shown you exactly who they are: risk-averse, reactive, and perfectly happy letting states do the dirty work. Federal reform will only happen when the politics of doing nothing become more dangerous than the politics of action, and we’re not there yet.
For operators, survival depends on mastering state markets, shaping local policies, and building businesses that can thrive without a federal safety net. For investors, this polling is a reminder that public support isn’t a shortcut to regulatory clarity. Washington isn’t coming to save cannabis. The question is whether the industry can save itself in the meantime.
From the hearing room to the comment section — we’re watching it all.
✊ As cannabis legalization spreads, social justice remains a driving force in shaping policy frameworks. Advocates argue that without equity-focused licensing, expungement, and reinvestment, legalization risks entrenching the same disparities prohibition created. (NUG Magazine) As industry leaders and policy makers, we shouldn’t just care about markets, but also about who gets to participate in them.
💰 A Chicago attorney is accused of running a $300,000 licensing scam, promising cannabis permits and political access that never materialized. The lawsuit, filed by Nectar Markets, underscores how high-dollar licensing schemes still plague the industry as new markets open. Consider it another reminder: in cannabis, shortcuts usually cost more than the long way around. (USA Herald)
🌱 European seed suppliers are making major inroads in the U.S. cannabis market, capitalizing on their reputations for quality genetics and consistent production. As domestic growers chase premiumization, expect more overseas players to shape trends stateside. (Cannabis Law Report)
🧬 Researchers have developed a nanomaterial from hemp fiber that shows promise in preventing infections and accelerating wound healing. The team behind the study says the material’s antimicrobial properties could have wide-ranging medical applications. (HempToday) Consider it another reminder: cannabis isn’t just a plant, it’s a platform for innovation.
🎥 Hollywood may hold the key to cannabis normalization. As TV and film shift from stoner clichés to nuanced portrayals of cannabis use, the cultural groundwork for policy change gets stronger. Operators should watch this space: entertainment shapes public opinion faster than any lobbying campaign. (Harris Sliwoski)
